Found: 78
Select item for more details and to access through your institution.
The Van Poznak/Estilo Article Reviewed.
- Published in:
- Oncology (08909091), 2006, v. 20, n. 9, p. 1065
- By:
- Publication type:
- Article
Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance.
- Published in:
- International Journal of Oncology, 2014, v. 45, n. 3, p. 1184, doi. 10.3892/ijo.2014.2511
- By:
- Publication type:
- Article
Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Loss of anti‐spike antibodies following mRNA vaccination for COVID‐19 among patients with multiple myeloma.
- Published in:
- Cancer Reports, 2023, v. 6, n. 5, p. 1, doi. 10.1002/cnr2.1803
- By:
- Publication type:
- Article
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 6, p. 722, doi. 10.1111/bjh.18593
- By:
- Publication type:
- Article
Estimating a normal reference range for serum B‐cell maturation antigen levels for multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 6, p. 1064, doi. 10.1111/bjh.16673
- By:
- Publication type:
- Article
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. 568, doi. 10.1111/bjh.17282
- By:
- Publication type:
- Article
Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 2, p. 272, doi. 10.1111/bjh.16752
- By:
- Publication type:
- Article
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 2, p. 283, doi. 10.1111/bjh.16158
- By:
- Publication type:
- Article
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 1, p. 60, doi. 10.1111/bjh.14992
- By:
- Publication type:
- Article
Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 1, p. 81, doi. 10.1111/bjh.14026
- By:
- Publication type:
- Article
Mood, Attention and Generosity.
- Published in:
- Personality & Social Psychology Bulletin, 1974, v. 1, n. 1, p. 402, doi. 10.1177/0146167274001001135
- By:
- Publication type:
- Article
Comparing effects of kyphoplasty, vertebroplasty, and non-surgical management in a systematic review of randomized and non-randomized controlled studies.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 8, p. 2061, doi. 10.1007/s00277-021-04555-3
- By:
- Publication type:
- Article
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 4, p. 1079, doi. 10.1007/s00277-020-04351-5
- By:
- Publication type:
- Article
The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.
- Published in:
- Annals of Hematology, 2019, v. 98, n. 3, p. 691, doi. 10.1007/s00277-019-03595-0
- By:
- Publication type:
- Article
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
- Published in:
- Annals of Hematology, 2011, v. 90, n. 2, p. 193, doi. 10.1007/s00277-010-1052-8
- By:
- Publication type:
- Article
Cryoglobulinemia: Better Treatments With Brighter Outcomes.
- Published in:
- 2013
- By:
- Publication type:
- Opinion
Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression—A single center retrospective study.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 4, p. 628, doi. 10.1111/ejh.14057
- By:
- Publication type:
- Article
Efficacy of venetoclax plus anti‐CD38 monoclonal antibody‐containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 2, p. 222, doi. 10.1111/ejh.13896
- By:
- Publication type:
- Article
Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 3, p. 318, doi. 10.1111/ejh.13666
- By:
- Publication type:
- Article
Predicting Outcomes and Monitoring Disease in Patients With Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 9, p. 484
- By:
- Publication type:
- Article
The Role of JAK Inhibitors in Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2019, v. 17, n. 9, p. 500
- By:
- Publication type:
- Article
The incidence of translocation t(11;14) among patients with multiple myeloma in a single clinic.
- Published in:
- American Journal of Clinical Pathology, 2024, v. 161, n. 1, p. 16, doi. 10.1093/ajcp/aqad103
- By:
- Publication type:
- Article
Bisphosphonates in multiple myeloma.
- Published in:
- Cancer (0008543X), 1997, v. 80, n. S8, p. 1661, doi. 10.1002/(SICI)1097-0142(19971015)80:8+<1661::AID-CNCR16>3.0.CO;2-Y
- By:
- Publication type:
- Article
Monoclonal Gammopathy of Undetermined Significance: Why Identification of These Patients and Assessment of Their Skeletons Is Important.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 4, p. 311, doi. 10.3816/CLM.2009.n.061
- By:
- Publication type:
- Article
Proteasome Inhibitors: Closing the Garbage Can Opens up New Therapeutic Options for Patients with B-Cell Malignancies.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, p. S182
- By:
- Publication type:
- Article
Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, n. 5, p. 346
- By:
- Publication type:
- Article
Arsenic Compounds in the Treatment of Multiple Myeloma: A New Role for a Historical Remedy.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 7, n. 3, p. 192
- By:
- Publication type:
- Article
MODELS FOR SYNGENEIC ADOPTIVE CHEMOIMMUNOTHERAPY OF MURINE LEUKEMIAS*.
- Published in:
- Annals of the New York Academy of Sciences, 1976, v. 276, n. 1, p. 573, doi. 10.1111/j.1749-6632.1976.tb41684.x
- By:
- Publication type:
- Article
The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.
- Published in:
- Therapeutic Advances in Hematology, 2014, v. 5, n. 6, p. 197, doi. 10.1177/2040620714552614
- By:
- Publication type:
- Article
The Medical Research Council Myeloma IX Trial: New Clinical Insights on the Anticancer Effects of Zoledronic Acid in Patients With Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 1, p. 2, doi. 10.1016/j.clml.2011.03.025
- By:
- Publication type:
- Article
A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 4, p. 336, doi. 10.1016/j.clml.2011.02.002
- By:
- Publication type:
- Article
Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.
- Published in:
- European Journal of Haematology, 2018, v. 100, n. 6, p. 621, doi. 10.1111/ejh.13058
- By:
- Publication type:
- Article
Risk of skin cancer in multiple myeloma patients: a retrospective cohort study.
- Published in:
- European Journal of Haematology, 2016, v. 97, n. 5, p. 439, doi. 10.1111/ejh.12748
- By:
- Publication type:
- Article
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
- Published in:
- European Journal of Haematology, 2010, v. 84, n. 3, p. 201, doi. 10.1111/j.1600-0609.2009.01384.x
- By:
- Publication type:
- Article
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
- Published in:
- European Journal of Haematology, 2009, v. 82, n. 6, p. 433, doi. 10.1111/j.1600-0609.2009.01244.x
- By:
- Publication type:
- Article
The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable.
- Published in:
- European Journal of Haematology, 2003, v. 70, n. 4, p. 263, doi. 10.1034/j.1600-0609.2003.t01-2-00011.x
- By:
- Publication type:
- Article
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
- Published in:
- Cancer (0008543X), 2005, v. 104, n. 10, p. 2141
- By:
- Publication type:
- Article
Bortezomib in recurrent and/or refractory multiple myeloma: Initial clinical experience in patients with impaired renal function.
- Published in:
- Cancer (0008543X), 2005, v. 103, n. 6, p. 1195
- By:
- Publication type:
- Article
Erratum.
- Published in:
- Cancer (0008543X), 2001, v. 91, n. 10, p. 1956, doi. 10.1002/1097-0142(20010515)91:10<1956::AID-CNCR1219>3.0.CO;2-F
- By:
- Publication type:
- Article
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
- Published in:
- 2001
- By:
- Publication type:
- journal article
A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
- Published in:
- 2001
- By:
- Publication type:
- journal article
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 523, doi. 10.1016/j.clml.2022.01.012
- By:
- Publication type:
- Article
Treatment With Elotuzumab in Combination With Dexamethasone Achieves a Complete Remission in a Previously Treated Patient With Multiple Myeloma: A Case Report.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranuloma Associated With Multiple Myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article